| Followers | 19 |
| Posts | 6547 |
| Boards Moderated | 1 |
| Alias Born | 05/23/2019 |
Tuesday, November 05, 2024 7:20:06 AM
WQLF SAYS : Wouldn’t it be nice if CV Sciences was AcQuired by this company? Check out their credentials 🪪. Have Mercy Have Faith Have Patience Have International Partners Have International Mergers & AcQusitions. WQLF Ahooooooo
“Cronos has a $1.8 billion investment from tobacco company Altria Group Inc., arming it with a war chest to fund acquisitions and grow its business. Altria paid that sum to acquire a 45% stake in Cronos along with warrants that, if exercised, would raise that stake to 55%.”
https://www.marketwatch.com/story/cronos-paid-300-million-for-a-small-cbd-company-and-ceos-private-equity-firm-stands-to-collect-120-million-of-it-2019-11-04
https://www.retaildive.com/news/cbd-cannabis-brand-lord-jones-exits-united-states-enters-canada/652172/
The Cronos Group CBD
Cronos Group Inc. is a global cannabinoid company that produces and distributes cannabis products, including CBD (Cannabidiol) products. Here’s a summary of key information:
Acquisitions: Cronos Group acquired Lord Jones, a US-based CBD company, for $300 million in 2019. Lord Jones sells CBD products such as beauty and skin-care products, tinctures, and edibles in the US and abroad.
CEO’s Private-Equity Firm: Cronos Group’s CEO, Mike Gorenstein, co-founded Gotham Green Partners, a private-equity firm that stood to collect 40% of the purchase price, including over $20 million in fees, from the Lord Jones acquisition.
Bank of America Upgrade: In 2019, Bank of America Merrill Lynch upgraded Cronos Group’s stock due to the company’s aggressive plans for a US CBD launch, citing CEO Mike Gorenstein’s comments on the company’s intentions.
CBD Market Potential: Cronos Group believes the CBD market has significant potential, with a growing demand for wellness products. The company is focused on building a strong brand portfolio and advancing research and technology to drive innovation.
Leadership: Mike Gorenstein serves as Cronos Group’s Chairman, President, and CEO, while Jeff serves as Chief Growth Officer, leading the Marketing, Innovation, Operations, and Sales teams in North America and globally.
Key Takeaways:
Cronos Group is a global cannabinoid company with a focus on CBD products.
The company acquired Lord Jones, a US-based CBD company, for $300 million in 2019.
Cronos Group’s CEO has a private-equity firm that benefited from the Lord Jones acquisition.
The company has received upgrades from Bank of America Merrill Lynch due to its aggressive plans for a US CBD launch.
Cronos Group is committed to building a strong brand portfolio and advancing research and technology to drive innovation in the CBD market.“
“Cronos has a $1.8 billion investment from tobacco company Altria Group Inc., arming it with a war chest to fund acquisitions and grow its business. Altria paid that sum to acquire a 45% stake in Cronos along with warrants that, if exercised, would raise that stake to 55%.”
https://www.marketwatch.com/story/cronos-paid-300-million-for-a-small-cbd-company-and-ceos-private-equity-firm-stands-to-collect-120-million-of-it-2019-11-04
https://www.retaildive.com/news/cbd-cannabis-brand-lord-jones-exits-united-states-enters-canada/652172/
The Cronos Group CBD
Cronos Group Inc. is a global cannabinoid company that produces and distributes cannabis products, including CBD (Cannabidiol) products. Here’s a summary of key information:
Acquisitions: Cronos Group acquired Lord Jones, a US-based CBD company, for $300 million in 2019. Lord Jones sells CBD products such as beauty and skin-care products, tinctures, and edibles in the US and abroad.
CEO’s Private-Equity Firm: Cronos Group’s CEO, Mike Gorenstein, co-founded Gotham Green Partners, a private-equity firm that stood to collect 40% of the purchase price, including over $20 million in fees, from the Lord Jones acquisition.
Bank of America Upgrade: In 2019, Bank of America Merrill Lynch upgraded Cronos Group’s stock due to the company’s aggressive plans for a US CBD launch, citing CEO Mike Gorenstein’s comments on the company’s intentions.
CBD Market Potential: Cronos Group believes the CBD market has significant potential, with a growing demand for wellness products. The company is focused on building a strong brand portfolio and advancing research and technology to drive innovation.
Leadership: Mike Gorenstein serves as Cronos Group’s Chairman, President, and CEO, while Jeff serves as Chief Growth Officer, leading the Marketing, Innovation, Operations, and Sales teams in North America and globally.
Key Takeaways:
Cronos Group is a global cannabinoid company with a focus on CBD products.
The company acquired Lord Jones, a US-based CBD company, for $300 million in 2019.
Cronos Group’s CEO has a private-equity firm that benefited from the Lord Jones acquisition.
The company has received upgrades from Bank of America Merrill Lynch due to its aggressive plans for a US CBD launch.
Cronos Group is committed to building a strong brand portfolio and advancing research and technology to drive innovation in the CBD market.“
Bullish
Recent CVSI News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 08:04:10 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 09:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:06:03 PM
- CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results • ACCESS Newswire • 03/26/2026 08:00:00 PM
- CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026 • ACCESS Newswire • 03/24/2026 09:00:00 PM
- CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth • ACCESS Newswire • 03/10/2026 09:00:00 PM
- CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness • ACCESS Newswire • 02/26/2026 01:30:00 PM
- CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD • ACCESS Newswire • 12/23/2025 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:19:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:04:08 PM
- CV Sciences, Inc. Reports Third Quarter 2025 Financial Results • ACCESS Newswire • 11/13/2025 09:00:00 PM
- CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025 • ACCESS Newswire • 11/10/2025 11:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:24:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 09:23:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2025 08:01:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2025 08:50:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2025 08:01:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/15/2025 09:25:41 PM
